Inhibition of (mono)amine oxidase activity and prevention of ifosfamide encephalopathy by methylene blue

Drug Metabolism and Disposition

Volumn 24, Issue 12, 1996, Pages 1336-1339

  Aeschlimann, C ^a   Cerny, T ^b   Kupfer A ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b University Hospital   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING); CHLOROACETALDEHYDE; IFOSFAMIDE; METHYLENE BLUE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN DISEASE; ENZYME ACTIVITY; ENZYME INHIBITION; GLUCONEOGENESIS; LIVER HOMOGENATE; LIVER MITOCHONDRION; LIVER PERFUSION; MALE; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT;

ALKYLATION; ANIMALS; ANTIDOTES; ANTINEOPLASTIC AGENTS; BRAIN DISEASES; CATTLE; IFOSFAMIDE; LIVER; MALE; METHYLENE BLUE; MICE; MONOAMINE OXIDASE INHIBITORS; PERFUSION; RATS; RATS, WISTAR;

ANIMALIA;

EID: 0030469591     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. T. Cerny and A. Küpfer: The enigma of ifosfamide encephalopathy. Ann. Oncol. 3, 679-681 (1992).
2. S. N. Wolff, R. H. Herzig, J. W. Fay, et al.: High-dose N,N,N-triethylene-thiophosphoramide (Thiotepa) with autologous bone marrow transplantation: phase I studies. Semin. Oncol. 17 (Suppl. 3), 2-6 (1990).
3. A. Küpfer, C. Aeschlimann, B. Wermuth, and T. Cerny: Prophylaxis and reversal of ifosfamide encephalopathy with methylene blue. Lancet 343, 763-764 (1994).
4. G. B. Zulian, E. Tullen, and B. Maton: Methylene blue for ifosfamide-associated encephalopathy. N. Engl. J. Med. 332, 1239-1240 (1995).
5. J. M. Ferrero, P. Eftekari, R. Largillier, G. Dreyfus, and M. Namer: Traitement d'une encéphalopathie à l'ifosfamide par le bleu de methylène. Bull. Cancer 82, 598-599 (1995).
6. J. L. Alonso, Y. Nieto, J. A. Lopez, M. Martin, and E. Diaz-Rubio: Ifosfamide encephalopathy and methylene blue: a case report. Ann. Oncol. 7, 643-645 (1996).
7. 2H-NMR spectroscopic studies on the metabolism and biochemical effect of 2-bromoethanamine in the rat. Biochem. Pharmacol. 49, 1349-1359 (1995).
8. A. Küpfer, C. Aeschlimann, B. Wermuth, T. M. Visarius, and T. Cerny: Experimental glutaric aciduria in rats: a new animal model for mitochondrial ifosfamide toxicity in man. Experientia, 52, 85 (1996).
9. M. P. Goren: Dechloroethylation of ifosfamide and neurotoxicity. Lancet 331, 1219-1220 (1986).
10. R. Neumann, R. Hevey, and R. H. Abeles: The action of plasma amine oxidase on beta-haloamines. J. Biol. Chem. 250, 6362-6367 (1975).
11. C. Aeschlimann, T. Cerny, and A. Küpfer: Chloroethylamine: a urinary metabolite of patients with high dose ifosfamide treatment. Naunyn-Schmiedebergs Arch. Pharmacol. 349, (abstr.) R130 (1994).
12. M. S. Highley, G. Momerency, K. Van Cauwenberghe, A. T. Van Oosterom, E. A. De Bruijn, R. A. A. Maes, P. Blake, J. Mansi, and P. G. Harper: Formation of chloroethylamine and 1,3-oxazolidine-2-one following ifastamide administration in humans. Drug Metab. Dispos. 23, 433-437 (1995).
13. A. Küpfer, T. Cerny, and J. R. Idle: Intramolecular rearrangement of ifosfamide in aqueous solutions. Lancet 335, 1461 (1990).
14. R. A. Peters: Lethal synthesis. Proc. R. Soc. Lond. (Ser. B) 139, 143-170 (1952).
15. B. Testa and P. Jenner. In "Drug Metabolism: Chemical and Biochemical Aspects," pp. 351. Marcel Dekker, Inc., New York, 1976.
16. V. Glover, M. A. Reveley, and M. Sandler: A monoamine oxidase inhibitor in human urine. Biochem. Pharmacol. 29, 467-470 (1980).
17. J. Reichen and M. Le: Verapamil favourably influences hepatic microvascular exchange and function in rats with cirrhosis of the liver. J. Clin. Invest. 78, 448-455 (1986).
18. USP-NF XXIII: "Official Monographs," p.790, US Pharmacopial Convention, Inc., Rockville, MD, 1985.
19. Y. P. Crippa, A. Küpfer, and T. Cerny: Comparative pharmacokinetics of ifosfamide and of chloroacetaldehyde following intravenous and oral ifosfamide administration in the rat. MD thesis, University of Berne, Switzerland, Departments of Clinical Pharmacology and Medical Oncology, 1990.
20. O. M. Friedman and E. Boger: Colorimetric estimation of the nitrogen mustards in aqueous media. Anal. Chem. 33, 906-910 (1961).
21. R. Preussmann, H. Schneider, and F. Epple: Untersuchungen zum Nachweis alkylierender Agentien. Der Nachweis verschiedener Klassen alkylierender Agentien mit einer Modifikation der Farbreaktion mit 4-(4′-Nitrobenzyl)-Pyridin. Arzneimittelforsch 7, 1059-1073 (1969).
22. A. Küpfer, C. Aeschlimann, and T. Cerny: Methylene blue and the neurotoxic mechanisms of ifosfamide encephalopathy. Eur. J. Clin. Pharmacol. 50, 249-252 (1996).
23. L. L. Madison, A. Lochner, and J. Wulff: Ethanol-induced hypoglycemia. II. Mechanism of suppression of hepatic gluconeogenesis. Diabetes 16, 252-258 (1967).
24. S. R. Greenberg and H. J. Kehr: Methylene-blue in alcohol-induced hypoglycemia. Lancet II, 1132 (1965).
25. P. R. Ryle, J. Chakraborty, and A. D. Thomson: The effect of methylene blue on the hepatocellular redox state and liver lipid content during chronic ethanol feeding in the rat. Biochem. J. 232, 877-882 (1985).
26. W. J. M. Hrushesky, R. O. Olshefski, P. Wood, S. Meshnick, and J. W. Eaton: Modifying intracellular redox balance: an approach to improving therapeutic index. Lancet I, 565-567 (1985).
27. A. R. Di Santo and J. G. Wagner: Pharmacokinetics of highly ionized drugs. I. Methylene blue - whole blood, urine and tissue assays. J. Pharm. Sci. 61, 598-602 (1972).
28. A. R. Di Santo and J. G. Wagner: Pharmacokinetics of highly ionized drugs. II. Methylene blue - absorption, metabolism and excretion in man and dog after oral administration. J. Pharm. Sci. 61, 1086-1091 (1972).
29. A. R. Di Santo and J. G. Wagner: Pharmacokinetics of highly ionized drugs. I. Methylene blue - whole blood, urine and tissue assays. J. Pharm. Sci. 61, 598-602 (1972).
30. A. Kozaki and J. Watanabe: Dose dependency of apparent volumes of distribution for methylene blue in rabbits. J. Pharmacobiodyn. 4, 49-57 (1981).
31. J. Watanabe and R. Fujita: Elimination of methylene blue in dogs after oral or intravenous administration. Chem. Pharm. Bull. 25, 2561-2567 (1977).
32. A. C. Beaumont, J. Gallagher, W. Hamann, and J. R. Wedley: The distribution of drugs administered using the Bier's technique. Anaesthesia 44, 529-530 (letter) (1989).
33. S. L. Narsapur and G. J. Naylor: Methylene blue. A possible treatment for manic depressive psychosis. J. Affec. Disord. 5, 155-161 (1983).
34. G. J. Naylor, A. H. Smith, and P. A. Connely: Methylene blue in mania. Biol. Psychiatry 24, 941-942 (letter) (1988).
35. G. J. Naylor, A. H. Smith, and P. A. Connely: Controlled trial of methylene blue in severe depressive illness. Biol. Psychiatry 22, 657-659 (1987).
36. W. J. Turner: Methylene blue for MDI. Biol. Psychiatry 20, 815 (letter) (1985).
37. R. D. Thomas and K. Callender: Methylene blue in treatment of bipolar illness. Biol. Psychiatry 20, 120-121 (letter) (1985).
38. J. P. Moody, S. M. Allan, A. H. Smith, and G. J. Naylor: Methylene blue excretion in depression. Biol. Psychiatry 26, 850-852 (letter) (1989).
39. T. M. Visarius, B. H. Lauterburg, A. Küpfer, and J. W. Stucki: Long chain fatty acid oxidation in mitochondria is inhibited by chloroacetaldehyde and restored by methylene blue. Experientia 52, 84 (1996).